检索结果-南通市图书馆

Propionyl-l-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases

World Journal of Gastroenterology 2012年第36期18卷 5065-5071页

作者： Giuseppe Merra Giovanni Gasbarrini lucrezia laterza Marco Pizzoferrato Andrea Poscia Franco Scaldaferri Vincenzo Arena Francesca Fiore Achille Cittadini Alessandro Sgambato Francesco Franceschi Antonio Gasbarrini Emergency Department Catholic University of Sacred Heart00168 RomeItaly Medical Research Foundation and nonprofit organization 40123 BolognaItaly Department of Internal Medicine and Gastroenterology Catholic University of Sacred Heart00168 RomeItaly Institute of Hygiene Catholic University of Sacred Heart00168 RomeItaly Institute of Pathology Catholic University of Sacred Heart00168 RomeItaly Department of Internal Medicine and Geriatry Catholic University of Sacred Heart00168 RomeItaly Institute of General Pathology Catholic University of Sacred Heart00168 RomeItaly

AIM:To assess clinical and endoscopic response to propionyl-l-carnitine hydrochloride(PlC) in colonic inflammatory bowel ***:Patients suffering from mild to moderate ulcerative colitis(UC) or Crohn's disease(CD) colitis,with disease activity index(DAI) between 3 and 10 and under stable therapy with oral aminosalicylates,mercaptopurine or azathioprine,for at least 8 wk prior to baseline assessments,were considered suitable for *** patients were enrolled to assume PlC 2 g/d(two active tablets twice daily) ***-endoscopic and histological activity were assessed by DAI and histological index(HI),respectively,following a colonoscopy performed immediately before and after 4 wk *** response was defined as a lowering of at least 3 points in DAI and clinical remission as a DAI score ≤ *** response was defined as an improvement of HI of at least 1 *** used median values for the *** pre-and post-treatment were analyzed by Wilcoxon signed rank ***:All patients enrolled completed the *** patient,despite medical advice,took deflazacort 5 d before follow-up colonoscopy *** side effects were reported by patients during the *** treatment,71%(SE 12%) of patients achieved clinical response,while 64%(SE 13%) obtained *** UC from CD patients,we observed a clinical response in 60%(SE 16%) and 100%,*** 60%(SE 16%) of UC patients and 75%(SE 25%) of CD patients were in clinical remission after *** median DAI was 7 [interquartile range(IQR):4-8] before treatment and decreased to 2(IQR:1-3)(P ly,in CD patients,although displaying a clear reduction of DAI from 7(IQR:5.5-7.5) before therapy to 1.5(IQR:0.5-2.5) after therapy,differences observed were not sign

关键词： propionyi-l-carnitine Ulcerative colitis Crohn's disease Inflammatory bowel disease therapy propionyi-l-carnitine hydrochloride

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：